Similarly, tumor-infiltrating CD3+, CD8+, activated CD4+, and activated CD8+ T cells, but not CD4+ T cells, were upregulated by treatment with cilengitide, AR-A014418, or WP1066 (Figure 6, B and C, and Supplemental Figure 10, A–D). This evidence concerns the gene CD8A and neoplasm.